Masayuki Takeda

6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: EVALUATION AND TREATMENT OF URINARY INCONTINENCE, PELVIC ORGAN PROLAPSE AND FAECAL INCONTINENCE

Paul Abrams, Karl‐Erik Andersson, Apostolos Apostolidis et al. · Neurourology and Urodynamics · 2018 · 1.1K citations · Full text

Urology, Please Note, Voiding Dysfunction +12

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba et al. · JAMA Oncology · 2017 · 978 citations

Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score

Yukio Homma, Masaki Yoshida, Narihito Seki et al. · Urology · 2006 · 731 citations

Symptom Assessment Tool, Urology, Voiding Dysfunction +4

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto et al. · Science Translational Medicine · 2011 · 658 citations

Cetuximab Sensitivity, Oncology, Erbb2 Signaling +15

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

Vivek Subbiah, Jürgen Wolf, Bhavana Konda et al. · The Lancet Oncology · 2022 · 384 citations · Full text

Thyroid Tumours, Medicine, Metronomic Therapy +9